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Conclusion  
Artificial measurements allow us to compare different 
pre-treatment verification methods in relatively quick 
way without occupancy of the linac time for 
measurements. Another benefit from our methodology is 
that the result is independent of the measurement’s 
uncertainties. Based on artificial measurements 
comparison we can decide on clinically adequate gamma 
criteria and percent of passing points levels for different 
devices and cancer sites. 
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Purpose or Objective  
Optimization of VMAT patient specific quality assurance 
(QA) through establishing the institutional local 
confidence limit by statistical analysis of gamma results. 
Material and Methods  
The VMAT patient specific plans for fifty VMAT cases 
were calculated in Varian Eclipse treatment planning 
system (TPS) and all the plans were executed in Varian 
Clinac Trilogy machine. Patient specific QA was 
performed using portal dosimetry (Varian) and Arc check 
device (Sun nuclear). The gamma criteria of 3% dose 
difference and 3mm distance to agreement was used to 
find the difference between TPS calculated and 
measured dose distribution. 
Area gamma, mean gamma and maximum gamma were 
calculated and tabulated for the TPS vs. measured planar 
dose using portal dosimetry. The percentage of pixels 
passing gamma of one was calculated and tabulated for 
the TPS vs. measured planar dose using Arc check device. 
The mean and standard deviation of the gamma results 
were calculated and the local confidence limit was 
derived by using the concept of ǀmeanǀ±1.96σ 
Results  
In portal dosimetry, the area gamma ≤1, average gamma 
and maximum gamma were 99.1±1.06, 0.26±0.05 and 
2.05±0.53 respectively with gamma criteria of 3% dose 
difference and 3mm distance to agreement. In Arch 
check, the average  percentage of pixels passed the 
gamma of one was 99.3±0.7. 
Local confidence limit derived for portal dosimetry area 
gamma, average gamma and maximum gamma were 97%, 
0.37 and 3.10 respectively. For Arc check, the confidence 
limit derived was 98% against the gamma criteria of 3%-
3mm. 
Conclusion  
The local confidence limit for gamma analysis using 
portal dosimetry and Arc check device was established. 
Every institution should establish their local confidence 
limit in order to optimize the patient specific QA based 
on their machine, QA device and type of plans. 
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Purpose or Objective  
Alanine is a passive solid-state dosimeter material with 
potential applications for remote auditing and dosimetry 
in complex fields or non-reference conditions. Alanine 
has a highly linear dose response which is essentially 
independent of dose rate and energy for clinical MV 
photon beams. Alanine is available as pellets with a 5 mm 
diameter, and irradiations in flatten-filter free beams or 
other non-uniform beams are therefore subject to volume 
averaging and EPR spectrometer cavity sensitivity 
correction. In this work, we report on a simple model 
that can provide volume and cavity sensitivity correction 
factors for improved output factor measurements in small 
MV photon beams. 
Material and Methods  
The x-ray beam was delivered by an Elekta Versa HD linac 
with an Agility MLC160 radiation head. Symmetric and 
square field sizes (FS) for 6 MV flattened filter free (FFF) 
beams were considered. The data were acquired at 
SSD=90 cm, depth 10 cm. The alanine pellets were the 
standard Harwell/NPL type (Ø4.83×2.80 mm). The pellets 
were placed in water with a latex sleeve to protect 
against water. A Bruker EMX-micro EPR spectrometer 
equipped with an EMX X-band high sensitivity resonator 
was used to read out the dose deposited in the alanine 
pellets. The beam profiles were measured using single 
detectors in a PTW MP3 water tank. A rotational 
symmetric Gaussian horizontal beam profile and 
exponential decaying depth dose profile in the vicinity of 
the pellet was fitted to the measured profiles. Cavity 
sensitivity correction functions found in literature (Anton 
et al. 2015) and in the technical manual of the Bruker 
spectrometer were used. 
Results  
The fit of the beam profile in three dimensions was based 
on two parameters: the variance for the Gaussian profile 
and the gradient of the depth profile. The parameters in 
turn were both changing as function of FS. Using the 
fitted beam profiles, an analytical model was developed 
for the calculation of volume and cavity sensitivity 
correction factors kV and kS for given FS (see Table 1). 
 
Table 1: Calculated volume correction factors kV, 
sensitivity correction factors kS (Anton/Bruker), 
temperature, volume, and sensitivity corrected output 
factors (OF) with SD being one standard deviation (SD) 
are displayed for the 6 MV FFF beam as function of the 
field size FS. 
Conclusion  
The cavity sensitivity correction was found to influence 
the alanine measurements in the range of 3 to 17 ‰ for 
the smallest field size depending on the cavity sensitivity 
correction function applied. A simple analytical 
expression for the correction factors as function of field 
size and the radius of the sensitive volume of the 
detector was obtained. The method presented here 
would be applicable for other detector geometries and 
beam energies. The cavity sensitivity correction was 
found to be small. The differences in the cavity 
sensitivity corrections functions (Anton/Bruker) might 
arise from the method used in detection of the cavity 
correction function and the applied spectrometer. 
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